Fibrinogen Human
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
FIBRINOGEN HUMAN: From Fibrinogen Replacement Therapy to Hemoglobinopathy
One-Sentence Summary
Fibrinogen Human (DrugBank DB09222) is a plasma-derived coagulation factor concentrate; its specific approved indication text is not available in this Evidence Pack, and the drug is currently not marketed under the reviewed regulatory dataset. The TxGNN model predicts potential relevance to Hemoglobinopathy with a 99.12% score, but on closer review the supporting evidence is weak: the single matched clinical trial is a data-linkage mismatch (different drug), and the 20 literature hits describe disease-related coagulation abnormalities in hemoglobinopathy patients rather than therapeutic use of exogenous fibrinogen — with some evidence pointing to a plausible safety concern instead of a benefit signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this Evidence Pack (no Taiwan license records; original_indications empty) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.12% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (original_moa: [Data Gap]), and no approved-indication text exists in the regulatory dataset for this drug. Based on general pharmacology, Fibrinogen Human is a plasma-derived coagulation factor concentrate used to correct fibrinogen deficiency and control bleeding; mechanistically, it acts by increasing circulating fibrinogen available for clot formation.
However, the actual evidence gathered for the hemoglobinopathy prediction does not support a straightforward “efficacy” narrative. The literature base is dominated by observational and mechanistic studies describing an endogenous hypercoagulable state already present in sickle cell disease and β-thalassemia (elevated fibrinogen, thrombin generation, platelet activation, fibrinogen-mediated RBC-endothelium adhesion). This is disease pathophysiology, not evidence that administering exogenous fibrinogen treats hemoglobinopathy. One review (PMID 33026614) further raises the possibility that exogenous fibrinogen may increase cardiovascular/thrombotic risk. Since hemoglobinopathy patients are already prone to hypercoagulability, supplementing a pro-coagulant factor in this population is mechanistically more plausible as a risk signal than a therapeutic opportunity. This should be treated as a caution flag rather than a confirmation of the TxGNN prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03673085 | Phase 1 | Completed | 32 | First-in-human dose-escalation PK/safety study of CN128 in thalassemia patients. ⚠ Data quality note: the investigational drug is CN128, not Fibrinogen Human — this appears to be a keyword-based false-positive match (disease-term overlap only) and does not constitute direct clinical evidence for this drug. |
No genuine Fibrinogen Human clinical trial in hemoglobinopathy is currently registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33026614 | 2020 | Review | Molecular Biology Reports | Discusses exogenous fibrinogen’s role in reducing surgical bleeding but also its potential to contribute to cardiovascular disease — a direct safety-relevant reference for this drug class. |
| 32777069 | 2020 | Cohort | Blood Advances | Fibrinogen mediates sickle RBC adhesion to ICAM-1, linked to right-to-left shunts in sickle cell disease — implicates fibrinogen in disease vascular pathology, not treatment. |
| 24609765 | 2014 | Cohort | Int J Hematology | Thromboelastometry shows a hypercoagulable profile in children with β-thalassemia. |
| 39441287 | 2024 | Observational | Georgian Medical News | Protein C/S evaluation in β-thalassemia major, correlated with hemoglobin, ferritin, D-dimer. |
| 35417875 | 2022 | Review/Cohort | Georgian Medical News | Documents thrombotic complications and latent hypercoagulation across β-thalassemia subtypes. |
| 14693325 | 2003 | Review | American Journal of Medicine | Reviews hypercoagulability in sickle cell disease, including elevated fibrinogen/thrombin activity. |
| 31648337 | 2019 | Review | Blood Advances | Describes coagulation system activation, including thrombin, as a driver of SCD pathophysiology and organ damage. |
| 27723451 | 2017 | Observational | Blood Transfusion | Platelet procoagulant properties and effect of transfusion in β-thalassaemia patients. |
| 1203541 | 1975 | Observational | Blut | Early study documenting hypercoagulability and hypofibrinolysis, with elevated fibrinogen levels, in sickle-cell disease. |
| 7272221 | 1981 | Observational | British Journal of Haematology | Erythrocyte deformability and blood viscosity changes during sickle-cell vaso-occlusive crisis. |
All 10 listed publications are disease-mechanism or observational studies describing coagulation abnormalities intrinsic to hemoglobinopathies. None report therapeutic administration of exogenous Fibrinogen Human to treat hemoglobinopathy.
US Market Information
No Taiwan marketing authorization is on record for this drug (market_status: 未上市, total_licenses: 0). No license/product data is available to tabulate.
Safety Considerations
No structured safety data (key warnings, contraindications, DDI) is available for this drug in the current dataset — all fields are marked as data gaps. Please refer to the package insert for safety information.
Additional signal surfaced during evidence review (not from structured safety fields): the literature base suggests hemoglobinopathy patients already exist in a hypercoagulable state; supplementing exogenous fibrinogen in this population carries a theoretical thrombotic/cardiovascular risk (per PMID 33026614) that should be explicitly evaluated before any further development is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is not corroborated by real evidence — the only matched clinical trial is a data-linkage false positive (wrong drug), and all 20 literature hits describe hemoglobinopathy-associated coagulation pathophysiology rather than therapeutic benefit from exogenous fibrinogen. There is also a plausible mechanistic safety concern (added thrombotic risk in an already hypercoagulable population) rather than a benefit signal. This corresponds to Evidence Level L5 (model prediction only) and Decision Stage S0.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action data (High-severity data gap, DG002)
- A genuine, drug-matched clinical trial or case series evaluating Fibrinogen Human in hemoglobinopathy patients
- A dedicated thrombotic-risk assessment for administering a pro-coagulant factor to an already hypercoagulable population
- Basic Taiwan/US regulatory and DDI data, none of which currently exist for this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.